Allarity Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALLR Nasdaq 2836 www.allarity.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Allarity Therapeutics, Inc.

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements - Nov 18th, 2024 1:00 pm
Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights - Nov 14th, 2024 1:00 pm
Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib - Oct 22nd, 2024 12:00 pm
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement - Oct 10th, 2024 12:00 pm
Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program - Oct 3rd, 2024 12:00 pm
Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial - Sep 16th, 2024 12:00 pm
Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 13th, 2024 12:45 pm
Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2) - Sep 11th, 2024 12:00 pm
Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting - Jul 26th, 2024 1:00 pm
Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares - Jul 24th, 2024 10:00 am
Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives - Jul 22nd, 2024 10:30 am
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance - Jun 27th, 2024 12:00 pm
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer - Jun 25th, 2024 12:00 pm
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement - May 20th, 2024 12:00 pm
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances - May 14th, 2024 8:01 pm
All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy - May 7th, 2024 4:00 pm
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock - May 7th, 2024 1:30 pm
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1 - May 6th, 2024 12:00 pm
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer - May 2nd, 2024 12:00 pm
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1) - Apr 17th, 2024 1:10 pm